Organon & Co (OGN)
15.28
+0.39
(+2.62%)
USD |
NYSE |
Nov 22, 16:00
15.35
+0.07
(+0.46%)
Pre-Market: 20:00
Organon Cash from Financing (Quarterly): -78.00M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -78.00M |
| June 30, 2024 | -134.00M |
| March 31, 2024 | -74.00M |
| December 31, 2023 | -77.00M |
| September 30, 2023 | -78.00M |
| June 30, 2023 | -88.00M |
| March 31, 2023 | -326.00M |
| December 31, 2022 | -82.00M |
| September 30, 2022 | -77.00M |
| June 30, 2022 | -183.00M |
| Date | Value |
|---|---|
| March 31, 2022 | -91.00M |
| December 31, 2021 | 169.00M |
| September 30, 2021 | -18.00M |
| June 30, 2021 | 233.00M |
| March 31, 2021 | -1.361B |
| December 31, 2020 | -677.00M |
| September 30, 2020 | -303.00M |
| June 30, 2020 | -577.00M |
| March 31, 2020 | -618.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.361B
Minimum
Mar 2021
233.00M
Maximum
Jun 2021
-233.68M
Average
-88.00M
Median
Jun 2023
Cash from Financing (Quarterly) Benchmarks
| ResMed Inc | -150.76M |
| TG Therapeutics Inc | 134.45M |
| Sage Therapeutics Inc | 1.037M |
| Applied Therapeutics Inc | 0.00 |
| Vor Biopharma Inc | 0.041M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 141.00M |
| Cash from Investing (Quarterly) | -75.00M |
| Free Cash Flow | 646.00M |
| Free Cash Flow Per Share (Quarterly) | 0.2502 |
| Free Cash Flow to Equity (Quarterly) | -28.00M |
| Free Cash Flow to Firm (Quarterly) | 283.52M |
| Free Cash Flow Yield | 16.37% |